Skip to content

Ketamine: all studies

Page 152 of 449: studies 1,511 to 1,520 of 4,486, newest first. Back to the ketamine overview

Research

Ketamine potentiates a central glutamatergic presynapse

bioRxiv Preprint Server December 17, 2023 Abdelmoneim Eshra, Noa Lipstein, Stefan Hallermann 1 citation preprint

Ketamine produces rapid and sustained antidepressant effects after brief exposure to a single dose. Counterintuitively, while ketamine acts primarily as a blocker of postsynaptic N-methyl-D-aspartate receptors (NMDARs), increased signalling at glutamatergic synapses has been reported. Due to technical limitations, however, it remains unclear whether ketamine directly increases presynaptic...

DOI: 10.1101/2023.12.17.571741 (opens in new tab) Full text (opens in new tab) Ketamine: ketamine Dissociative anesthetic Antidepressant drug Antidepressants: antidepressants +15

Short-term ketamine use in bipolar depression: a review of the evidence for short-term treatment management

Frontiers in Psychiatry December 8, 2023 Alina Wilkowska, Wiesław Jerzy Cubała 10 citations

Bipolar depression constitutes a major problem in psychiatry. It correlates with high suicidality, treatment resistance, chronicity, and poor quality of life. Registered treatment for bipolar depression is limited and insufficient. There is an urgent need for implementing new therapeutic strategies. Intranasal ketamine’s enantiomer—esketamine is a novel rapid-acting antidepressant with proven...

Preliminary evidence that ketamine alters anterior cingulate resting-state functional connectivity in depressed individuals

Translational Psychiatry December 3, 2023 Laith Alexander, Peter C. T. Hawkins, Jennifer W. Evans et al. 26 citations

Abstract Activity changes within the anterior cingulate cortex (ACC) are implicated in the antidepressant effects of ketamine, but the ACC is cytoarchitectonically and functionally heterogeneous and ketamine’s effects may be subregion specific. In the context of a double-blind randomized placebo-controlled crossover trial investigating the clinical and resting-state fMRI effects of intravenous...

Enhanced TARP-γ8-PSD-95 coupling in excitatory neurons contributes to the rapid antidepressant-like action of ketamine in male mice

Nature Communications December 2, 2023 Shi-Ge Xue, Jin-Gang He, Ling-Li Lu et al.

Ketamine produces rapid antidepressant effects at sub-anesthetic dosage through early and sustained activation of α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors (AMPARs), however, the exact molecular mechanism still remains unclear. Transmembrane AMPAR regulatory protein-γ8 (TARP-γ8) is identified as one of AMPAR auxiliary subunits, which controls assemblies, surface trafficking...

Oral ketamine may offer a solution to the ketamine conundrum

Psychopharmacology December 1, 2023 Megan Dutton, Adem T. Can, Jim Lagopoulos et al.

Abstract Ketamine has received considerable attention for its rapid and robust antidepressant response over the past decade. Current evidence, in clinical populations, predominantly relates to parenterally administered ketamine, which is reported to produce significant undesirable side effects, with additional concerns regarding long-term safety and abuse potential. Attempts to produce a...

Esketamine accelerates emergence from isoflurane general anaesthesia by activating the paraventricular thalamus glutamatergic neurones in mice.

British Journal of Anaesthesia December 1, 2023 Wenying Duan, Kang Peng, Hui-Min Qin et al.

BACKGROUND Delayed emergence from general anaesthesia poses a significant perioperative safety hazard. Subanaesthetic doses of ketamine not only deepen anaesthesia but also accelerate recovery from isoflurane anaesthesia; however, the mechanisms underlying this phenomenon remain elusive. Esketamine exhibits a more potent receptor affinity and fewer adverse effects than ketamine and exhibits...

The mechanistic basis for the rapid antidepressant-like effects of ketamine: From neural circuits to molecular pathways.

Progress in Neuro-Psychopharmacology and Biological Psychiatry December 1, 2023 Li Ren

Conventional antidepressants that target monoaminergic receptors require several weeks to be efficacious. This lag represents a significant problem in the currently available treatments for serious depression. Ketamine, acting as an N-methyl-d-aspartate receptor antagonist, was shown to have rapid antidepressant-like effects, marking a significant advancement in the study of mood disorders....

Ketamine-Assisted Psychodynamic Psychotherapy.

Psychodynamic psychiatry December 1, 2023 John G Cottone

This case report details the treatment of a longtime psychodynamic psychotherapy patient, with a particular focus on a ketamine-assisted psychotherapy (KAP) session, and how the progress achieved during this session compares with the literature on KAP. The patient is a 54-year-old woman with a history of multiple traumas, including sexual assault and life-threatening physical injuries, as well...

The use of ketamine in psychiatric therapy

Hellenic Journal of Nursing Science December 1, 2023 Angeliki Statharou, Crysodimitra Galatou, Evangelos Pergadas

Introduction: Ketamine was used for the first time in 1962 in Veterinary Medicine as an anesthetic and analgesic drug. For decades it was used as a narcotic substance, more widely known as “Special K”, i.e. a recreational drug. In recent years, the scientific community has focused on its remarkable and immediate therapeutic effect on depressed patients, who showed a remission of symptoms in a...

Prolonged ketamine therapy differentially rescues psychobehavioural deficits via modulation of nitro-oxidative stress and oxytocin receptors in the gut-brain-axis of chronically-stressed mice.

Psychoneuroendocrinology December 1, 2023 Edem Ekpenyong Edem, Oluwatomisn Adeyosola Oguntala, Daniel Akinwale Ikuelogbon et al. 4 citations

Ketamine is an anaesthetic known to have short but rapid-acting anti-depressant effects; however, the neurobehavioural effects of its prolonged use and its role on the oxytocin system in the gut-brain axis are largely undetermined. Female BALB/c mice were either exposed to the chronic unpredictable mild stress (CUMS) paradigm for 21 days and then treated with ketamine in four doses for 14 days...

DOI: 10.1016/j.psyneuen.2023.106370 (opens in new tab) Full text (opens in new tab) Ketamine Depression-associated behaviours Gut-brain axis Oxidative/nitrergic stress +1